 Following a rough outing throughout much of this year, biopharmaceutical firm Inhibrx NASDAQ: INBX finally gave stakeholders reason to smile. Earlier today, the company announced it discussed with the Food and Drug Administration FDA matters associated with its key therapeutic INBRX-101. 